Sansure Biotech Inc.
Symbol: 688289.SS
SHH
20.62
CNYTržní cena dnes
31.0215
Poměr P/E
0.0048
Poměr PEG
11.83B
MRK Cap
- 0.03%
Výnos DIV
Sansure Biotech Inc. (688289-SS) finanční výkazy
Rozvaha
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 4781.8 | 5663.8 | 4682.7 | |||||||
balance-sheet.row.short-term-investments | 0 | 548.3 | 2451.2 | 2046.5 | |||||||
balance-sheet.row.net-receivables | 0 | 732.8 | 1472.7 | 894.1 | |||||||
balance-sheet.row.inventory | 0 | 376.6 | 355.3 | 369.5 | |||||||
balance-sheet.row.other-current-assets | 0 | 58.4 | 33.6 | 20 | |||||||
balance-sheet.row.total-current-assets | 0 | 5949.6 | 7525.4 | 5966.2 | |||||||
balance-sheet.row.property-plant-equipment-net | 0 | 1055.2 | 785.3 | 481 | |||||||
balance-sheet.row.goodwill | 0 | 7.7 | 0 | 0 | |||||||
balance-sheet.row.intangible-assets | 0 | 328 | 84.4 | 45.6 | |||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 335.6 | 84.4 | 45.6 | |||||||
balance-sheet.row.long-term-investments | 0 | 974.3 | -1793.8 | -1533.2 | |||||||
balance-sheet.row.tax-assets | 0 | 73.8 | 69.6 | 25 | |||||||
balance-sheet.row.other-non-current-assets | 0 | 65.6 | 2502.8 | 2105.8 | |||||||
balance-sheet.row.total-non-current-assets | 0 | 2504.6 | 1648.3 | 1124.1 | |||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.total-assets | 0 | 8454.2 | 9173.8 | 7090.4 | |||||||
balance-sheet.row.account-payables | 0 | 468.7 | 791.4 | 258.7 | |||||||
balance-sheet.row.short-term-debt | 0 | 77.2 | 14.3 | 8.5 | |||||||
balance-sheet.row.tax-payables | 0 | 17.7 | 216.4 | 101.3 | |||||||
balance-sheet.row.long-term-debt-total | 0 | 18.2 | 13.6 | 6.4 | |||||||
Deferred Revenue Non Current | 0 | 32.5 | 30.5 | 25.7 | |||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||
balance-sheet.row.other-current-liab | 0 | 340.5 | 712.9 | 2.4 | |||||||
balance-sheet.row.total-non-current-liabilities | 0 | 77.7 | 89.3 | 45.1 | |||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.capital-lease-obligations | 0 | 18.2 | 13.6 | 6.4 | |||||||
balance-sheet.row.total-liab | 0 | 996.8 | 1661 | 709 | |||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.common-stock | 0 | 588.5 | 588.5 | 400 | |||||||
balance-sheet.row.retained-earnings | 0 | 4882.7 | 5077.1 | 3820 | |||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 395.2 | 377.4 | 294 | |||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 1334.9 | 1457.7 | 1854.9 | |||||||
balance-sheet.row.total-stockholders-equity | 0 | 7201.3 | 7500.6 | 6368.9 | |||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 8454.2 | 9173.8 | 7090.4 | |||||||
balance-sheet.row.minority-interest | 0 | 223.6 | 12.2 | 12.4 | |||||||
balance-sheet.row.total-equity | 0 | 7424.9 | 7512.8 | 6381.3 | |||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||
Total Investments | 0 | 1522.6 | 657.4 | 513.2 | |||||||
balance-sheet.row.total-debt | 0 | 95.4 | 27.9 | 14.9 | |||||||
balance-sheet.row.net-debt | 0 | -4138 | -3184.7 | -2621.3 |
Výkaz peněžních toků
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |||
---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 1936.7 | 2242.5 | 2616.6 | ||||||
cash-flows.row.depreciation-and-amortization | 0 | 89.1 | 53.9 | 26.7 | ||||||
cash-flows.row.deferred-income-tax | 0 | -40 | -8.1 | -4.6 | ||||||
cash-flows.row.stock-based-compensation | 0 | 60.8 | 5.6 | 4.6 | ||||||
cash-flows.row.change-in-working-capital | 0 | 203.3 | -402.1 | -50.4 | ||||||
cash-flows.row.account-receivables | 0 | -496.5 | -304.1 | -419.4 | ||||||
cash-flows.row.inventory | 0 | -282.1 | -93 | -212.1 | ||||||
cash-flows.row.account-payables | 0 | 496.5 | 3.1 | 585.7 | ||||||
cash-flows.row.other-working-capital | 0 | 485.4 | -8.1 | -4.6 | ||||||
cash-flows.row.other-non-cash-items | 0 | 308.9 | -14.8 | 49.4 | ||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -558.8 | -372.9 | -108.7 | ||||||
cash-flows.row.acquisitions-net | 0 | -11.6 | 15.9 | 115 | ||||||
cash-flows.row.purchases-of-investments | 0 | -12140.6 | -7880 | -3725 | ||||||
cash-flows.row.sales-maturities-of-investments | 0 | 11591.1 | 7125.6 | 2111.3 | ||||||
cash-flows.row.other-investing-activites | 0 | -46.9 | -0.9 | -108.7 | ||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -1166.7 | -1112.2 | -1716 | ||||||
cash-flows.row.debt-repayment | 0 | -17.2 | -55 | -55 | ||||||
cash-flows.row.common-stock-issued | 0 | 274.6 | 200 | 0 | ||||||
cash-flows.row.common-stock-repurchased | 0 | -257.4 | -200 | 0 | ||||||
cash-flows.row.dividends-paid | 0 | -656.9 | -439.9 | -301.3 | ||||||
cash-flows.row.other-financing-activites | 0 | -259 | -193.7 | 1966.2 | ||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -915.9 | -688.6 | 1609.9 | ||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | -10 | -34.3 | -44.6 | ||||||
cash-flows.row.net-change-in-cash | 0 | 466.2 | 42 | 2491.6 | ||||||
cash-flows.row.cash-at-end-of-period | 0 | 3099.1 | 2632.8 | 2590.8 | ||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 2632.8 | 2590.8 | 99.2 | ||||||
cash-flows.row.operating-cash-flow | 0 | 2558.9 | 1877.1 | 2642.3 | ||||||
cash-flows.row.capital-expenditure | 0 | -558.8 | -372.9 | -108.7 | ||||||
cash-flows.row.free-cash-flow | 0 | 2000.1 | 1504.2 | 2533.6 |
Řádek výkazu zisku a ztráty
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 1002.5 | 6450.4 | 4514.5 | |||||||
income-statement-row.row.cost-of-revenue | 0 | 381.8 | 2655.4 | 1279 | |||||||
income-statement-row.row.gross-profit | 0 | 620.7 | 3795 | 3235.5 | |||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||
income-statement-row.row.other-expenses | 0 | 10.6 | 95.5 | 44.5 | |||||||
income-statement-row.row.operating-expenses | 0 | 638.7 | 1262.2 | 666.9 | |||||||
income-statement-row.row.cost-and-expenses | 0 | 1020.5 | 3917.5 | 1945.9 | |||||||
income-statement-row.row.interest-income | 0 | 54.7 | 48.4 | 32.5 | |||||||
income-statement-row.row.interest-expense | 0 | 2.4 | 2.1 | 0.8 | |||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||
income-statement-row.row.total-other-income-expensenet | 0 | 450.7 | -23.9 | -5.6 | |||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||
income-statement-row.row.other-operating-expenses | 0 | 10.6 | 95.5 | 44.5 | |||||||
income-statement-row.row.total-operating-expenses | 0 | 450.7 | -23.9 | -5.6 | |||||||
income-statement-row.row.interest-expense | 0 | 2.4 | 2.1 | 0.8 | |||||||
income-statement-row.row.depreciation-and-amortization | 0 | 136.8 | 290.8 | -20.7 | |||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||
income-statement-row.row.operating-income | 0 | -18 | 2339.8 | 2621.8 | |||||||
income-statement-row.row.income-before-tax | 0 | 432.6 | 2315.9 | 2616.2 | |||||||
income-statement-row.row.income-tax-expense | 0 | 62.3 | 379.2 | 373.7 | |||||||
income-statement-row.row.net-income | 0 | 363.7 | 1936.8 | 2242.7 |
Často kladené otázky
Co je Sansure Biotech Inc. (688289.SS) celková aktiva?
Sansure Biotech Inc. (688289.SS) celková aktiva jsou 8454204974.000.
Jaký je roční obrat podniku?
Roční příjmy jsou N/A.
Jaké je ziskové rozpětí podniku?
Zisková marže firmy je 0.729.
Jaký je volný peněžní tok podniku?
Volný peněžní tok je -0.496.
Jaká je čistá zisková marže podniku?
Čistá zisková marže je 0.321.
Jaké jsou celkové tržby podniku?
Celkové příjmy jsou 0.334.
Co je Sansure Biotech Inc. (688289.SS) čistý zisk (čistý příjem)?
Čistý zisk (čistý příjem) je 363721131.000.
Jaký je celkový dluh podniku?
Celkový dluh je 95444005.000.
Jaké je číslo provozních nákladů?
Provozní výdaje jsou 638676546.000.
Jaké je číslo peněžních prostředků firmy?
Peněžní prostředky podniku jsou 0.000.